Method Development
Design, optimize, and validate bioanalytical methods aligned with FDA/ICH guidance. Establish sensitivity, selectivity, precision, accuracy, and stability parameters tailored to vaccine antigens, adjuvants, and excipients.
Accelerate preclinical evaluation with end-to-end bioanalytical testing for vaccine components. We align assay design, validation, and reporting to FDA/ICH guidance, covering immunogenicity, potency, stability, and impurity profiling. Submission-ready deliverables and coordinated logistics streamline timelines for sponsors and research organizations.
Preclinical bioanalysis for vaccine components, from assay design to validation, sample analysis, and submission-ready reporting.
Design, optimize, and validate bioanalytical methods aligned with FDA/ICH guidance. Establish sensitivity, selectivity, precision, accuracy, and stability parameters tailored to vaccine antigens, adjuvants, and excipients.
Measure immune responses and potency with orthogonal assays, including binding assays and neutralization formats, to characterize vaccine performance across preclinical studies and inform dose selection.
Characterize stability, purity, and impurities using chromatographic and mass spectrometry approaches. Support forced-degradation studies, release criteria, and comparability assessments for vaccine components.
We define targets, matrices, and endpoints for vaccine components, map timelines, and align on acceptance criteria. Together we finalize an assay panel and documentation plan consistent with FDA/ICH bioanalytical guidelines to support preclinical decision-making.
Real outcomes from research sponsors and developers who streamlined preclinical milestones.
A single, compliant partner to coordinate materials, methods, and measurable results.
Documentation and methods aligned with FDA/ICH guidance for audit-ready bioanalysis.
Consolidate sourcing, logistics, and analytical testing to reduce handoffs and risk.
Validated handling and temperature control to protect sensitive vaccine components.
Robust supply network and partnerships supporting sponsors across the U.S., China, and beyond.
Experienced leadership guiding complex studies.
Chief Executive Officer, Ph.D., MPA
Hao Wang leads VuRoyal Pharmaceutical with a background spanning pharmaceutical R&D and clinical research. He has moderated scientific forums on vaccine adjuvants and oversees strategic partnerships that enhance access to specialized materials and analytics. Hao champions rigorous documentation, regulatory alignment, and efficient study execution so sponsors can advance preclinical vaccine programs with confidence. His focus on collaboration and knowledge-sharing helps translate complex science into clear, submission-ready deliverables.
A bioanalytical laboratory develops, validates, and performs assays to measure drugs, biologics, and biomarkers in biological matrices. For vaccines, labs quantify antigens, assess adjuvants, evaluate immune responses, and characterize impurities or degradation products, generating data packages and reports that support preclinical decision-making and regulatory submissions.
Talk to our experts about your assay plan.
Verified FDA registration status.
Drug business quality certification.
State-approved license status.
Share your vaccine component, matrices, target endpoints, and timelines. We’ll propose an assay and validation plan with clear milestones and deliverables.
For immediate assistance, feel free to give us a direct call at +1 617-870-2690 You can also send us a quick email at
For immediate assistance, feel free to give us a direct call at +1 617-870-2690 You can also send us a quick email at